Entering text into the input field will update the search result below

Enrollment underway in Catalyst Pharma's second late-stage study of Firdapse in LEMS

Dec. 15, 2016 8:56 AM ETCatalyst Pharmaceuticals, Inc. (CPRX) StockCPRXBy: Douglas W. House, SA News Editor
  • The first patient has been enrolled in the second Phase 3 study, LMS-003, assessing Catalyst Pharmaceuticals' (NASDAQ:CPRX) Firdapse (amifampridine phosphate) for the treatment Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder characterized by muscle weakness in the limbs.
  • LMS-003 will enroll ~28 subjects and will have the same co-primary endpoints as the first Phase 3 trial. Top-line data and the resubmission of a New Drug Application (NDA) to the FDA should happen in H2 2017.
  • The FDA issued a "Refusal to File" letter in February in response to the company's first NDA, which meant that the filing was incomplete and required additional supporting data.
  • Amifampridine enhances neuromuscular transmission by blocking the potassium channel. This causes depolarization of the presynaptic membranes which opens the calcium channel thereby enabling muscle fibers to contract.
  • Previously: FDA rejects Catalyst Pharma's Firdapse NDA; shares slump 38% (Feb. 17)

Recommended For You

More Trending News

About CPRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CPRX--
Catalyst Pharmaceuticals, Inc.